Back to News
Market Impact: 0.3
Roche's Divarasib Cuts Death Risk By 44% In Phase 3 KRAS G12C-Mutated Lung Cancer Study
Source: Nasdaq
Healthcare & BiotechCompany Fundamentals
Genentech, a member of Roche Group, reported pivotal Phase 3 KRASCENDO 1 results showing investigational divarasib had superior efficacy to current standard-of-care KRAS G12C inhibitors in people with previously treated disease. The excerpt provides no numerical efficacy results or further details.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.35
More News
- From Wall Street to Silicon Valley, Anthropic IPO poised to have massive 'trickle-down effect'
- Microsoft offers buyouts to nearly 30% of workforce in ongoing AI shift
- Anthropic’s risk factors include the end of humanity, a feud with the Pentagon, and CEO Dario Amodei’s reputation
- Elon Musk warns more than 200 AI cloud companies face ‘guppy-level death’ as the AI boom runs into a debt crisis
- Why is PagSeguro Digital stock plummeting 30% today?
- Anthropic’s IPO filing shows explosive growth, risks and staggering costs